ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $18.42.

ALXO has been the topic of several recent analyst reports. Stifel Nicolaus reissued a “hold” rating and set a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. Jefferies Financial Group raised ALX Oncology from a “hold” rating to a “buy” rating and upped their price target for the company from $8.00 to $18.00 in a research report on Friday, December 8th.

ALX Oncology Trading Up 2.0 %

Shares of ALXO opened at $11.41 on Friday. The business’s 50-day moving average price is $14.15 and its 200 day moving average price is $11.10. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $572.23 million, a P/E ratio of -3.04 and a beta of 1.63. ALX Oncology has a 1-year low of $3.94 and a 1-year high of $17.42.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Analysts expect that ALX Oncology will post -3.33 earnings per share for the current year.

Insider Buying and Selling

In other ALX Oncology news, CAO Shelly Pinto sold 2,717 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $13.60, for a total value of $36,951.20. Following the transaction, the chief accounting officer now owns 78,591 shares in the company, valued at $1,068,837.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ALX Oncology news, CEO Jason Lettmann acquired 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was purchased at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Shelly Pinto sold 2,717 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $13.60, for a total value of $36,951.20. Following the transaction, the chief accounting officer now owns 78,591 shares in the company, valued at $1,068,837.60. The disclosure for this sale can be found here. 50.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in ALX Oncology by 49.0% in the 4th quarter. Vanguard Group Inc. now owns 1,502,409 shares of the company’s stock valued at $22,371,000 after buying an additional 494,173 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of ALX Oncology in the fourth quarter worth about $1,201,000. American International Group Inc. lifted its position in shares of ALX Oncology by 24.1% during the 4th quarter. American International Group Inc. now owns 13,398 shares of the company’s stock worth $199,000 after purchasing an additional 2,600 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in ALX Oncology during the 4th quarter valued at approximately $8,090,000. Finally, Legal & General Group Plc grew its holdings in ALX Oncology by 42.6% in the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after buying an additional 684 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.